Browse by Clinical Topic:


Featured CME/CE Content:
 
neuroscienceCME Editors' Picks:



Live Q&A: @MondayNightIBD: Addressing the Cases That Challenge Your Practice

Premiere Date: Wednesday, September 30, 2020

This activity offers CE credit for:

  1. Physicians (CME)
  2. Pharmacists (ACPE)
  3. Other


All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Thursday, September 30, 2021
Note: Credit Is No Longer Available

Faculty


Aline Charabaty, MD, AGAFAline Charabaty, MD, AGAF 
Clinical Director of Gastroenterology
Director of Inflammatory Bowel Disease Center
Sibley Memorial Hospital
Assistant Professor of Medicine
Johns Hopkins School of Medicine
Washington, DC

Miguel Regueiro, MD, AGAF, FACG, FACPMiguel Regueiro, MD, AGAF, FACG, FACP 
Chair, Digestive Disease and Surgery
Chair, Department of Gastroenterology, Hepatology, and Nutrition
The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology
Professor, Department of Medicine
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Cleveland, OH

Statement of Need

Gastroenterologists are trailblazers in health care social media, and @MondayNightIBD has harnessed that energy to establish gastroenterologists as not just social media influencers but as clinical practice influencers as well. @MondayNightIBD is not just a weekly social media conversation - it is an international platform that is moving the field forward by crowdsourcing the expertise of leading inflammatory bowel disease (IBD) experts, community clinicians, and patients to meet the many challenges of IBD.

This live question and answer session is your opportunity to ask questions of our expert faculty. The original virtual symposium discussed a series of patient cases with the goal of helping clinicians better understand, share, and implement optimal management strategies for IBD. To view the full activity ahead of this live Q&A, click here.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Apply efficacy, safety, and comparative effectiveness data for existing and emerging therapies to optimize therapy selection for patients with IBD.
  • Identify appropriate treatment strategies for special populations with IBD such as pregnant/lactating women, the elderly, and patients with Clostridioides difficile infection (CDI).
  • Develop strategies, such as disease monitoring, therapeutic drug monitoring (TDM), shared decision-making (SDM), and patient education, to achieve optimal patient outcomes.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Explain efficacy, safety, and comparative effectiveness data for existing and emerging therapies to optimize therapy selection for patients with IBD.
  • Identify appropriate treatment strategies for special populations with IBD such as pregnant/lactating women, the elderly, and patients with CDI.
  • Describe strategies, such as disease monitoring, TDM, SDM, and patient education, to achieve optimal patient outcomes.

Financial Support

Supported by educational grants from AbbVie Inc.; Takeda Pharmaceuticals U.S.A.; Inc.; and UCB, Inc.

Target Audience

Gastroenterologists, primary care physicians, PAs, nurse practitioners, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hour (0.05 CEUs). Universal Activity Number:
Live: 0376-0000-20-123-L01-P

Type: knowledge-based

Note to PAs: PAs may claim a maximum of .5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME or a recognized state medical society.

Credit request forms and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately. This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Charabaty reports that she serves on the advisory committee for Janssen Pharmaceuticals, Inc. She is a consultant for AbbVie Inc.; Janssen Pharmaceuticals, Inc; and Pfizer Inc.

Dr. Regueiro reports that he receives research support from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.; He is on advisory boards and a consultant for AbbVie Inc.; Allergan; Amgen Inc.; Celgene Corporation; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Miraca Laboratories; Pfizer Inc.; Salix Pharmaceuticals; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.

Olga Askinazi, PhD (planning committee) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty has been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).

MMQ-100-093020-90

Home      |      Register/Log In      |      Activities      |      Communities of Practice      |      About      |      Download